JERSEY CITY, N.J., May 3, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global iPSCs Manufacturing Services Market by (Applications (Research Products, Drug Development & Discovery, Cellular Therapy, Toxicology Screening, Personalized Medicine, Disease Modelling, Stem Cell Banking, and Emerging Applications), End-user (Pharmaceutical & Biotechnology Companies, Academic institutes, Research Laboratories & CROs, Hospitals & Surgical Centres, Cell & Tissue Banks, and Other End Users)) - Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
According to the latest market research, the Global iPSCs Manufacturing Services Market is valued at US$ 1009.00 Million in 2021, and it is expected to reach US$ 2611.94 Million by 2030, with a CAGR of 11.5% during the forecast period of 2022-2030.
Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1223
Induced pluripotent stem cells are derived from skin or blood cells (iPSCs). They're cells that have been reprogrammed from somatic cells using various transcription factors. Such cells have the ability to self-renew and can develop into any of the 220+ distinct kinds of human cells. iPSC has certain advantages over other stem cell types. iPSCs are used to produce regenerative medicines, wound healing models and patient-specific cells, which can be transplanted to the site of injury or tissue degeneration due to various disease conditions. iPSC has several essential properties, including the ability to use ample donor somatic cells, eliminate histocompatibility issues with donor/recipient transplants, and its use in drug discovery and developmental investigations.
Personalized medicine research and production and extended application of regenerative medicines are prominent growth factors of the iPSCs manufacturing market. Rising research and development trials on cardiac syndromes and neuropathies will strengthen the market growth. iPSC manufacturing industry growth is boosted by the automated platform, reducing the cost and increasing production, and new expansions and strategic collaborations support it. Moreover, iPSC production will be aided by clinical trials and research on disorders such as Parkinson's disease, anaemia, and cardiac syndromes. The adoption of an automated platform in the production of iPS cells will improve the market by lowering costs and increasing productivity. Ncardia created CellisticTM in April 2022, with the goal of focusing Ncardia's induced pluripotent stem cell (iPSC) capabilities on cell therapy development and production.
However, expensive therapies and uncertainty in differentiated tissues will hamper the production of iPSCs soon. Also, mass production processes and methods are under continuous development, which may inhibit the growth in the forecasting period.
Regionally, North America is expected to lead the manufacturing services market in the forecast period, followed by Europe due to fast research on neuropathies, cardiac diseases, and personalized medicine production. Also, extensive funding for development in the manufacturing of iPSC will be responsible for the growth.
Request for Proposal/ ToC: https://www.insightaceanalytic.com/request-sample/1223
Significant market key players are I Peace Inc., Lonza Group AG, Axol Bioscience Ltd., FUJIFILM Cellular Dynamics, Inc., Ncardia, Cynata Therapeutics Limited, Evotec SE, Celogics Inc, Catalent, Inc, CCRM, Applied StemCell Inc. (ASC), RoslinCT, Takara Bio Inc, Thermo Fisher Scientific, Inc, Other Prominent Players
Key Developments in the market:
- In April 2022, Ncardia launched a new business, Cellistic, to focus Ncardia's induced pluripotent stem cell (iPSC) expertise on cell therapy development and manufacturing. The expansion is to focus dedicated resources and capabilities to address the growing need for iPSC cell therapy solutions, including developing robust cell-specific manufacturing platforms.
- In Nov 2020, FUJIFILM Cellular Dynamics and Lonza signed an agreement that enables drug developers to leverage both companies' expertise and technologies to generate iPSCs through licensing agreements.
- In May 2021, BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics announced a strategic R&D association to discover and develop cell therapies for eye diseases. The companies will merge their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases.
- In Oct 2020, Axol Biosciences announced the expansion of its service offering, with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. This expansion supports pre-clinical research by optimizing human iPSC-derived cell culture while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.
Obtain Latest Published Report Details @ https://www.insightaceanalytic.com/report/global-ipscs-manufacturing-services-market/1223
Global iPSCs Manufacturing Services Market, by By Applications, 2022-2030 (Value US$ Mn)
- Research Products
- Drug Development & Discovery
- Cellular Therapy
- Toxicology Screening
- Personalized Medicine
- Disease Modelling
- Stem Cell Banking
- Emerging Applications
Global iPSCs Manufacturing Services Market, by End-user, 2022-2030 (Value US$ Mn)
- Pharmaceutical & Biotechnology Companies
- Academic institutes, Research Laboratories & CROs
- Hospitals & Surgical Centres
- Cell & Tissue Banks
- Other End Users
Global iPSCs Manufacturing Services Market, by Region, 2022-2030 (Value US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America iPSCs Manufacturing Services Market, by Country, 2022-2030 (Value US$ Mn)
- U.S.
- Canada
Europe iPSCs Manufacturing Services Market, by Country, 2022-2030 (Value US$ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific iPSCs Manufacturing Services Market, by Country, 2022-2030 (Value US$ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America iPSCs Manufacturing Services Market, by Country, 2022-2030 (Value US$ Mn)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa iPSCs Manufacturing Services Market, by Country, 2022-2030 (Value US$ Mn)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Why should buy this report:
- To receive a comprehensive analysis of the prospects for the global iPSCs Manufacturing Services Market
- To receive an industry overview and future trends of the iPSCs Manufacturing Services Market
- To analyze iPSCs Manufacturing Services Market drivers and challenges
- To get information on the iPSCs Manufacturing Services Market size (Value US$ Mn) forecast to 2030
- Significant investments, mergers & acquisitions in the iPSCs Manufacturing Services Market industry
For More Information @https://www.insightaceanalytic.com/report/global-ipscs-manufacturing-services-market/1223
Other Related Reports Published by InsightAce Analytic:
Global Allogeneic Cell Therapy Manufacturing Market
Global Stem Cell Exosome Therapeutic Market
Global mRNA Synthesis and Manufacturing Services Market
Global Immuno-Oncology Cell Therapy Market
Global Allogeneic Cell Therapies Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
Priyanka Tilekar
InsightAce Analytic Pvt. Ltd.
Asia: +91 79 72967118
Tel: +1 551 226 6109
Email: info@insightaceanalytic.com
Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
